Center for Translationel Forskning

Medicin og biovidenskab

1. Acetylcysteine 12%
2. alpha-Synuclein 25%
3. Antibodies 12%
4. Antioxidants 15%
5. Appetite Regulation 9%
6. Asthma 10%
7. BCG Vaccine 19%
8. Brain 18%
9. Case-Control Studies 11%
10. Chronic Obstructive Pulmonary Disease 31%
11. Clinical Studies 15%
12. Cognition 20%
13. Cognitive Dysfunction 15%
14. Cohort Studies 69%
15. Comorbidity 11%
16. Confidence Intervals 17%
17. Coronavirus 48%
18. Coronavirus Infections 13%
19. coronavirus receptor 12%
20. Cross-Over Studies 29%
21. Delivery of Health Care 22%
22. Denmark 79%
23. Diet 11%
24. Dipeptidyl-Peptidase IV Inhibitors 10%
25. Dyspnea 13%
26. Early Warning Score 17%
27. Eating 10%
28. Equivalence Trials 9%
29. exendin (9-39) 11%
30. gastric inhibitory polypeptide receptor 15%
31. Gastrointestinal Neoplasms 10%
32. Gene Expression 9%
33. Geriatrics 10%
34. Glucagon 23%
35. Glucagon-Like Peptide 1 13%
36. Glucagon-Like Peptide-1 Receptor 39%
37. Glucokinase 9%
38. Glucose 43%
39. Glycocalyx 9%
40. Health Personnel 12%
41. Heart Failure 13%
42. Hospital Emergency Service 34%
43. Hospitalization 21%
44. Hydroxybutyrates 11%
45. Hyperglycemia 10%
46. Hyperoxia 28%
47. Hypoglycemia 23%
48. Hypoglycemic Agents 18%
49. Infections 16%
50. Insulin 13%
51. Ketone Bodies 16%
52. Ketones 20%
53. Liraglutide 9%
54. Mannose-Binding Lectin 19%
55. metabotropic glutamate receptor 2 10%
56. Mortality 42%
57. Multiple System Atrophy 23%
58. Muscle Strength 14%
59. Neurodegenerative Diseases 11%
60. Obesity 23%
61. Observational Studies 61%
62. Occupational Groups 21%
63. Oxygen 27%
64. Pandemics 27%
65. Parkinson Disease 18%
66. Passive Immunization 11%
67. Peptides 23%
68. Perfusion Index 10%
69. Phenotype 9%
70. Placebos 48%
71. Polypharmacy 18%
72. Pragmatic Clinical Trials 12%
73. Prefrontal Cortex 12%
74. Prepulse Inhibition 11%
75. Prospective Studies 34%
76. Psoriatic Arthritis 17%
77. Quality of Life 22%
78. Randomized Controlled Trials 50%
79. Registries 10%
80. Respiratory Rate 11%
81. RNA 11%
82. SARS Virus 25%
83. Sensory Gating 19%
84. Sepsis 11%
85. Seroepidemiologic Studies 9%
86. Severe Acute Respiratory Syndrome 36%
87. Short Bowel Syndrome 9%
88. Sitagliptin Phosphate 10%
89. Sodium-Glucose Transport Proteins 16%
90. Synucleinopathies 20%
91. Synucleins 20%
92. Systematic Reviews 11%
93. Systemic Inflammatory Response Syndrome 12%
94. Therapeutics 16%
95. Transcutaneous Blood Gas Monitoring 11%
96. Type 1 Diabetes Mellitus 12%
97. Type 2 Diabetes Mellitus 100%
98. Vaccination 14%
99. Vital Signs 53%
100. Wounds and Injuries 10%